Evaluation of Prostate-Specific Antigen (PSA) Levels in Patients With Advanced Prostate Cancer Treated With Bicalutamide

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

340 participants

Study Classification

OBSERVATIONAL

Study Start Date

2009-03-31

Study Completion Date

2010-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Prospective, non-comparative, non-interventional, observational study to collect and analyse real life environment data on advanced prostate cancer patients receiving combination treatment of medical or surgical castration and bicalutamide according to routine medical practice in Croatia. The main aim is to evaluate change of PSA level and prescribing practices based on prostate cancer stage.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer

NCT01251861

Recurrent Prostate Carcinoma Stage I Prostate Cancer AJCC v7 Stage IIA Prostate Cancer AJCC v7 +2 more

ACTIVE_NOT_RECRUITING PHASE2

A Study to Test if Enzalutamide is Effective and Safe in Prostate Cancer Patients Who Have Never Had Hormone Therapy

NCT01302041

Prostate Cancer

COMPLETED PHASE2

Bicalutamide Compared With Observation Followed by Bicalutamide Plus Either Goserelin or Orchiectomy in Treating Patients With Prostate Cancer

NCT00014586

Prostate Cancer

TERMINATED PHASE3

Bicalutamide Monotherapy Has Significant Quality of Life Benefits for Men With Advanced Prostate Cancer

NCT00551044

Prostatic Neoplasms

COMPLETED NA

A Study of Enzalutamide Versus Bicalutamide in Castrate Men With Metastatic Prostate Cancer

NCT01288911

Prostatic Neoplasms

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Advanced Prostate Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with diagnosis of advanced prostate cancer
* Patients who are already treated with bicalutamide for at least 4 weeks and maximum 12 weeks
* Patients capable of signing ICF

Exclusion Criteria

* Patients with hypersensitivity to bicalutamide
* Patients on therapy with terfenadin, astemizol or cisapride
* Participation in a clinical study during the last 30 days

Minimum Eligible Age

40 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

No